Literature DB >> 17121532

Expression of activin and inhibin subunits, receptors and binding proteins in human adrenocortical neoplasms.

J Hofland1, M A Timmerman, W W de Herder, R H N van Schaik, R R de Krijger, F H de Jong.   

Abstract

OBJECTIVE: The growth and differentiation factors activin and inhibin can affect tumour formation and steroid production in the adrenal cortex. These factors bind to type I (Alk-4), type II (ActRIIA, ActRIIB) and type III (betaglycan) receptors or to the activin-binding protein follistatin. Expression of these activin-related mRNAs was measured in different types of adrenocortical tissues and tumours to study the relationship with tumorigenesis.
DESIGN: Quantitative expression of activin-related mRNAs was investigated in patient adrenocortical samples. PATIENTS: Twenty-eight human adrenocortical samples from normal and hyperplastic adrenals and from adrenocortical adenomas and carcinomas were collected after surgery for study purposes. MEASUREMENTS: Using quantitative reverse transcription polymerase chain reaction (RT-PCR), we investigated the expression of inhibin alpha-, betaA- and betaB-subunits, follistatin, betaglycan, ActRIIA, ActRIIB and Alk-4 in the adrenocortical tissues. The expression of cytochrome P450c17 (CYP17) mRNA was also measured to investigate its association with inhibin and activin subunit expression.
RESULTS: All genes studied were expressed in all tissues, with the exception of the inhibin alpha-subunit in one hyperplastic adrenal and three adrenocortical carcinomas. Expression of inhibin betaA-subunit, follistatin, betaglycan, ActRIIA, ActRIIB and CYP17 differed between nontumorous adrenals and carcinomas.
CONCLUSIONS: These differences, together with correlation analysis, indicate parallel regulation of the expression of CYP17, the inhibin alpha-subunit, ActRIIA, ActRIIB, betaglycan and follistatin. We conclude that the expression of activin and inhibin subunits, receptors and binding proteins is affected by tumour formation in the adrenal gland and may play a role in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17121532     DOI: 10.1111/j.1365-2265.2006.02668.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  5 in total

1.  ACTH is a potent regulator of gene expression in human adrenal cells.

Authors:  Yewei Xing; C Richard Parker; Michael Edwards; William E Rainey
Journal:  J Mol Endocrinol       Date:  2010-05-11       Impact factor: 5.098

2.  Exploration of Potential Ewing Sarcoma Drugs from FDA-Approved Pharmaceuticals through Computational Drug Repositioning, Pharmacogenomics, Molecular Docking, and MD Simulation Studies.

Authors:  Mubashir Hassan; Muhammad Yasir; Saba Shahzadi; Andrzej Kloczkowski
Journal:  ACS Omega       Date:  2022-06-01

3.  Inhibin/activin expression in human and rodent liver: subunits α and βB as new players in human hepatocellular carcinoma?

Authors:  K Frost; K Seir; A Lackner; M Grusch; B Grasl-Kraupp; R Schulte-Hermann; C Rodgarkia-Dara
Journal:  Br J Cancer       Date:  2011-03-15       Impact factor: 7.640

4.  Inhibin alpha-subunit (INHA) expression in adrenocortical cancer is linked to genetic and epigenetic INHA promoter variation.

Authors:  Johannes Hofland; Jacobie Steenbergen; Jacoba M Voorsluijs; Michael M P J Verbiest; Ronald R de Krijger; Leo J Hofland; Wouter W de Herder; Andre G Uitterlinden; Richard A Feelders; Frank H de Jong
Journal:  PLoS One       Date:  2014-08-11       Impact factor: 3.240

5.  ACTH-independent macronodular adrenocortical hyperplasia reveals prevalent aberrant in vivo and in vitro responses to hormonal stimuli and coupling of arginine-vasopressin type 1a receptor to 11β-hydroxylase.

Authors:  Johannes Hofland; Leo J Hofland; Peter M van Koetsveld; Jacobie Steenbergen; Wouter W de Herder; Casper H van Eijck; Ronald R de Krijger; Francien H van Nederveen; Maarten O van Aken; Johannes W de Groot; Thera P Links; Frank H de Jong; Richard A Feelders
Journal:  Orphanet J Rare Dis       Date:  2013-09-13       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.